This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cardiac complications & contraindications

Authoring team

High plasma concentrations of the non-sedative antihistamines may be achieved by several means:

  • simple overdose

  • slowing the rate of hepatic excretion:
    • by competing for the specific cytochrome P450 isoenzyme in the liver e.g. erythromycin and the antifungal imidazoles
    • as a result of hepatic failure

High doses of non-sedative antihistamines prolong the cardiac QT interval and predispose to arrythmias such as ventricular fibrillation and torsade de pointes.

Thus, the following precautions should be observed when prescribing non-sedative antihistamines:

  • do not exceed the recommended dose

  • avoid simultaneous administration of:
    • antifungal imidazoles e.g. ketoconazole
    • macrolide antibiotics e.g. erythromycin

  • avoid simultaneous administration of drugs which prolong the QT interval, including amiodarone, bretylium, disopyramide, procainamide, quinidine, sotalol, neuroleptic drugs and tricyclic antidepressants

  • potassium or magnesium depletion is a contraindication

  • symptomatic liver disease is a contraindication

  • pre-existing QT prolongation (> 450 ms) is a contraindication

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.